⚕ GalenOps field
←

SITE002-0069

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-05-20

AEs
8
Serious
0
Dropout signal
–

Adverse events

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 6); relationship: not assessed

mild assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 28); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-18 (study day 48); relationship: N

mild assessed

Grade 1 Asthenia — outcome: UNKNOWN; onset 2022-08-10 (study day 71); relationship: Y

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 85); relationship: Y

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 126); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 153); relationship: N

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-12 (study day 165); relationship: not assessed

Data queries

No data queries.